Mycetoma Caused by Madurella mycetomatis: A completely neglected medico-social dilemma

Advances in Experimental Medicine and Biology

Volumn 764, Issue , 2013, Pages 179-189

  Van Belkum, Alex ^a   Fahal, Ahmed ^b   Van De Sande, Wendy W J ^c  

^a BIOMÉRIEUX   (France)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; AROMATASE; CASPOFUNGIN; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 1B1; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MELANIN; POSACONAZOLE; TERBINAFINE; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; VORICONAZOLE;

AGE; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; FINE NEEDLE ASPIRATION BIOPSY; FUNGAL VIRULENCE; FUNGUS GROWTH; GENE FREQUENCY; HEALTH CARE MANAGEMENT; HEALTH EDUCATION; HIGH RISK POPULATION; HOST SUSCEPTIBILITY; HUMAN; HYGIENE; INFECTION PREVENTION; MADURELLA MYCETOMATIS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MYCETOMA; NEUTROPHIL; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK MANAGEMENT; SOCIAL PROBLEM; SOCIOECONOMICS; SUDAN;

EID: 84873605371     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4726-9_15     Document Type: Article

References (57)

1. Ahmed AO, Van Leeuwen W, Fahal A, Van de Sande W, Verbrugh H, Van Belkum A (2004) Mycetoma caused by Madurella mycetomatis: A neglected infectious burden. Lancet Infect Dis 4(9):566-5744
2. McGinnis MR (1996) Mycetoma. Dermatol Clin 14(1):97-1044
3. Padhi S, Uppin SG, Uppin MS, Umabala P, Challa S, Laxmi V, Prasad VB (2010) Mycetoma in South India: Retrospective analysis of 13 cases and description of two cases caused by unusual pathogens: Neoscytalidium dimidiatum and Aspergillus flavus. Int J Dermatol 49(11):1289-12966
4. Afroz N, Khan N, Siddiqui FA, Rizvi M (2010) Eumycetoma versus actinomycetoma: Diagnosis on cytology. J Cytol 27(4):133-1355
5. Wethered DB, Markey MA, Hay RJ, Mahgoub ES, Gumaa SA (1987) Ultrastructural and immunogenic changes in the formation of mycetoma grains. J Med Vet Mycol 25(1):39-466
6. Ahmed A, Adelmann D, Fahal A, Verbrugh H, Van Belkum A, de Hoog S (2002) Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan. J Clin Microbiol 40(3):1031-10366
7. Ahmed AO, Abugroun E, Fahal AH, Zijlstra EE, Van Belkum A, Verbrugh HA (1998) Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol 36:850-8511
8. Ameen M, Arenas R (2009) Developments in the management of mycetomas. Clin Exp Dermatol 34(1):1-77
9. Ahmed AO, Desplaces N, Leonard P, Goldstein F, De Hoog S, Verbrugh H, Van Belkum A (2003) Molecular detection and identification of agents of eumycetoma: Detailed report of two cases. J Clin Microbiol 41(12):5813-58166
10. Fahal AH, el Toum EA, el Hassan AM, Mahgoub ES, Gumaa SA (1995) The host tissue reaction to Madurella mycetomatis: New classification. J Med Vet Mycol 33(1):15-177
11. Ameen M, Arenas R (2008) Emerging therapeutic regimes for the management of mycetomas. Expert Opin Pharmacother 9(12):2077-20855
12. Mahgoub ES, Gumaa SA (1984) Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg 78:376-3799
13. Fahal AH, Rahman IA, El-Hassan AM, Rahman ME, Zijlstra EE (2011) The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 105(3):127-1322
14. Ahmed AO, Van de Sande WW, Van Vianen W, Van Belkum A, Fahal AH, Verbrugh HA, Bakker-Woudenberg IA (2004) In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-base 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-5- ((phenylamino)carbonyl)-2Htetrazolium hydroxide (XTT) assay. Antimicrob Agents Chemother 48(7):2742-27466
15. Van de Sande WW, Luijendijk A, Ahmed AO, Bakker-Woudenberg IA, Van Belkum A (2005) Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- ((phenylamino) carbonyl)-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method. Antimicrob Agents Chemother 49(4):1364-13688
16. de Hoog GS, Adelmann D, Ahmed AO, Van Belkum A (2004) Phylogeny and typification of Madurella mycetomatis, with a comparison of other agents of eumycetoma. Mycoses 47(3-4):121-1300
17. Desnos-Ollivier M, Bretagne S, Dromer F, Lortholary O, Dannaoui E (2006) Molecular identification of black-grain mycetoma agents. J Clin Microbiol 44(10):3517-35233
18. Padhye AA, Salkin IF (2011) Madurella pseudomycetomatis: An invalidly published name. J Clin Microbiol 49(4):17033
19. Ahmed AO, Mukhtar MM, Kools-Sijmons M, Fahal AH, de Hoog S, Van den Ende BG, Zijlstra EE, Verbrugh H, Abugroun ES, Elhassan AM, Van Belkum A (1999) Development of a species-specific PCRrestriction fragment length polymorphism analysis procedure for identification of Madurella mycetomatis. J Clin Microbiol 37(10):3175-31788
20. Ahmed A, Van de Sande W, Verbrugh H, Fahal A, Van Belkum A (2003) Madurella mycetomatis strains from mycetoma lesions in Sudanese patients are clonal. J Clin Microbiol 41(10):4537-45411
21. Fahal AH, Abu S (2010) Mycetoma in children. Trans R Soc Trop Med Hyg 104:107-1122
22. Yousif MA, Hay RJ (1987) Leucocyte chemotaxis to mycetoma agents - The effect of the antifungal drugs griseofulvin and ketoconazole. Trans R Soc Trop Med Hyg 81(2):319-3211
23. Van de Sande WW, Janse DJ, Hira V, Goedhart H, Van Der Zee R, Ahmed AO, Ott A, Verbrugh H, Van Belkum A (2006) Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J Immunol 177(3):1997-20055
24. Zaini F, Moore MK, Hathi D, Hay RJ, Noble WC (1991) The antigenic composition and protein profiles of eumycetoma agents. Mycoses 34(1-2):19-288
25. Romero H, Mackenzie DW (1989) Studies on antigens from agents causing black grain eumycetoma. J Med Vet Mycol 27(5):303-3111
26. Jiang RS, Hsu CY (2004) Serum immunoglobulins and IgG subclass levels in sinus mycetoma. Otolaryngol Head Neck Surg 130(5):563-5666
27. Araujo MJ, Castaneda E (1997) Madurella mycetomatis antigen for the serodiagnosis of mycetoma. Rev Iberoam Micol 14(1):31-355
28. de Klerk N, de Vogel C, Fahal A, Van Belkum A, Van de Sande WW (2011) Fructose-bisphosphate aldolase and pyruvate kinase, two novel immunogens in Madurella mycetomatis. Med Mycol (Epub ahead of print)\\
29. Rajendran C, Baby A, Kumari S, Verghese T (1991) An evaluation of straw-extract agar media for the growth and sporulation of Madurella mycetomatis. Mycopathologia 115(1):9-122
30. Van de Sande WW, Gorkink R, Simons G, Ott A, Ahmed AO, Verbrugh H, Van Belkum A (2005) Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size. J Clin Microbiol 43(9):4349-43566
31. Vos P, Hogers R, Bleeker M, Reijans M, Van de Lee T, Hornes M, Frijters A, Pot J, Peleman J, Kuiper M et al (1995) AFLP: A new technique for DNA fingerprinting. Nucleic Acids Res 23(21):4407-44144
32. Van Belkum A, Fahal AH, Van de Sande WW (2011) In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother 55(4):1771-17733
33. N'diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R (2006) Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol 45(2):154-1577
34. Van de Sande WW, Fahal AH, Bakker-Woudenberg IA, Van Belkum A (2010) Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. Antimicrob Agents Chemother 54(6):2738-27400
35. Mahgoub ES, Gumaa SA (1984) Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg 78(3):376-3799
36. Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A (2005) Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 47(6):339-3466
37. Van de Sande WW, Fahal AH, Riley TV, Verbrugh H, Van Belkum A (2007) In vitro susceptibility of Madurella mycetomatis, prime agent of Madura foot, to tea tree oil and artemisinin. J Antimicrob Chemother 59(3):553-5555
38. Wassenaar TM, Gaastra W (2001) Bacterial virulence: Can we draw the line? FEMS Microbiol Lett 201(1):1-77
39. Findlay GH, Vismer HF (1974) Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in Madurella mycetomi infection. Br J Dermatol 91(3):297-3033
40. Revankar SG, Sutton DA (2010) Melanized fungi in human disease. Clin Microbiol Rev 23(4):884-9288
41. Van de Sande WW, de Kat J, Coppens J, Ahmed AO, Fahal A, Verbrugh H, Van Belkum A (2007) Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect 9(9):1114-11233
42. Martinez LR, Ntiamoah P, Gacser A, Casadevall A, Nosanchuk JD (2007) Voriconazole inhibits melanization in Cryptococcus neoformans. Antimicrob Agents Chemother 51(12):4396-44000
43. Rid R, Simon-Nobbe B, Langdon J, Holler C, Wally V, Poll V, Ebner C, Hemmer W, Hawranek T, Lang R, Richter K, MacDonald S, Rinnerthaler M, Laun P, Mari A, Breitenbach M (2008) Cladosporium herbarum translationally controlled tumor protein (TCTP) is an IgE-binding antigen and is associated with disease severity. Mol Immunol 45(2):406-4188
44. Van de Sande WW, Fahal A, Verbrugh H, Van Belkum A (2007) Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol 179(5):3065-30744
45. Mahgoub ES, Gumaa SA, El Hassan AM (1977) Immunological status of mycetoma patients. Bull Soc Pathol Exot Filiales 70(1):48-544
46. Mahgoub ES (1978) Experimental infection of athymic nude New Zealand mice, nu nu strain with mycetoma agents. Sabouraudia 16(3):211-2166
47. Gumaa SA, Abu-Samra MT (1981) Experimental mycetoma infection in the goat. J Comp Pathol 91(3):341-3466
48. Nishimura K, Miyaji M (1985) Pathogenicity of Exophiala jeanselmei for ddY mice. Mycopathologia 91(1):29-333
49. Ahmed AO, Van Vianen W, ten Kate MT, Van de Sande WW, Van Belkum A, Fahal AH, Verbrugh HA, Bakker-Woudenberg IA (2003) A murine model of Madurella mycetomatis eumycetoma. FEMS Immunol Med Microbiol 37(1):29-366
50. Greenberg AK, Knapp J, Rom WN, Addrizzo-Harris DJ (2002) Clinical presentation of pulmonary mycetoma in HIV-infected patients. Chest 122(3):886-8922
51. Van de Sande WW, Fahal A, Tavakol M, Van Belkum A (2010) Polymorphisms in catechol-O-methyltransferase and cytochrome p450 subfamily 19 genes predispose towards Madurella mycetoma-tis-induced mycetoma susceptibility. Med Mycol 48(7):959-9688
52. Kuijpers TW (2002) Clinical symptoms and neutropenia: The balance of neutrophil development, functional activity, and cell death. Eur J Pediatr 161(Suppl 1):S75-822
53. Newport MJ, Finan C (2011) Genome-wide association studies and susceptibility to infectious diseases. Brief Funct Genomics 10(2):98-1077
54. Shugart YY, Wang Y, Jia WH, Zeng YX (2011) GWAS signals across the HLA regions: Revealing a clue for common etiology underlying infectious tumors and other immunity diseases. Chin J Cancer 30(4):226-2300
55. Zhang J, Chiodini R, Badr A, Zhang G (2011) The impact of next-generation sequencing on genomics. J Genet Genomics 38(3):95-1099
56. Ostergaard P, Simpson MA, Jeffery S (2011) Massively parallel sequencing and identification of genes for primary lymphoedema: A perfect fit. Clin Genet 80(2):110-1166
57. Morelli G, Song Y, Mazzoni CJ, Eppinger M, Roumagnac P, Wagner DM, Feldkamp M, Kusecek B, Vogler AJ, Li Y, Cui Y, Thomson NR, Jombart T, Leblois R, Lichtner P, Rahalison L, Petersen JM, Balloux F, Keim P, Wirth T, Ravel J, Yang R, Carniel E, Achtman M (2010) Yersinia pestis genome sequencing identifies patterns of global phylogenetic diversity. Nat Genet 42(12):1140-11433